Form 4: Gossamer Bio Director, Sandra Milligan, Acquires 115,000 Stock Options

Director Sandra Milligan acquired 115,000 non-qualified stock options in Gossamer Bio, Inc. on June 6, 2024, as part of the Non-Employee Director Compensation Program.

Summary

• On June 6, 2024, Sandra Milligan, a director of Gossamer Bio, Inc., acquired 115,000 non-qualified stock options.
• These options were granted as part of the Non-Employee Director Compensation Program.
• The exercise price of each option is $0.60.
• The options vest and become exercisable on the earlier of the first anniversary of the grant date or the next annual meeting of the Issuer's stockholders, contingent upon continued service on the board.
• The options expire on June 5, 2034.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to director compensation, which is generally viewed neutrally to positively as it aligns director interests with shareholders. There are no indications of negative sentiment.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service on the board.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

This is a standard practice for compensating non-employee directors in publicly traded companies, aligning their interests with shareholders through equity ownership.

Comparison to Industry Standards

• Granting stock options to non-employee directors is a common practice in the biotechnology industry.
• The vesting schedule and exercise price are typical for such grants.
• Comparable companies like Amgen, Biogen, and Gilead Sciences also utilize stock options as part of their director compensation packages.

Stakeholder Impact

• Shareholders may view this positively as it aligns the director's interests with the company's long-term success.
• The director is incentivized to contribute to the company's growth and profitability.

Key Dates